Publications

Updates and information on MPN therapy progress

Visit here often for the latest updates and to access relevant resources pertaining to treatment and support for the MPN community.

Publications

Real-world experience with Ropeginterferon-alpha 2b (Besremi) in Philadelphia-negative myeloproliferative neoplasms

Learn more →

Ropeginterferon Alfa-2b Induces High Rates of Clinical, Hematological and Molecular Responses in Polycythemia Vera: Two-Year Results from the First Prospective Randomized Controlled Trial

Learn more →

Evidence for Superior Efficacy and Disease Modification after Three Years of Prospective Randomized Controlled Treatment of Polycythemia Vera Patients with Ropeginterferon Alfa-2b Vs. HU/BAT

Learn more →

Thromboembolic Risk Reduction and High Rate of Complete Molecular Response with Long-Term Use of Ropeginterferon Alpha-2b in Polycythemia Vera: Results from a Randomized Controlled Study

Learn more →

Helpful Resources

Ropeginterferon alfa-2b is an investigational therapy not approved for use in the U.S.